NewAmsterdam Pharma (NAMS) Common Equity (2021 - 2026)

NewAmsterdam Pharma (NAMS) has 6 years of Common Equity data on file, last reported at $665.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 14.43% year-over-year to $665.2 million; the trailing twelve-month figure through Mar 2026 stood at $665.2 million (down 14.43% YoY), and the FY2025 full-year result was $683.4 million, down 9.78% from the prior year.
• Common Equity eased to $665.2 million in Q1 2026, from $683.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $778.5 million in Q2 2025 to a low of $288.4 million in Q4 2023.
• A 5-year average of $532.5 million and a median of $453.1 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 767.87% in 2022 and slumped 41.66% in 2023, its largest moves.
• Tracing NAMS's Common Equity over 5 years: stood at $494.3 million in 2022, then tumbled by 41.66% to $288.4 million in 2023, then surged by 162.66% to $757.5 million in 2024, then fell by 9.78% to $683.4 million in 2025, then slipped by 2.66% to $665.2 million in 2026.
• Business Quant data shows NAMS's Common Equity at $665.2 million in Q1 2026, $683.4 million in Q4 2025, and $728.1 million in Q3 2025.